BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

38 related articles for article (PubMed ID: 38593780)

  • 1. A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds.
    Bruna A; Rueda OM; Greenwood W; Batra AS; Callari M; Batra RN; Pogrebniak K; Sandoval J; Cassidy JW; Tufegdzic-Vidakovic A; Sammut SJ; Jones L; Provenzano E; Baird R; Eirew P; Hadfield J; Eldridge M; McLaren-Douglas A; Barthorpe A; Lightfoot H; O'Connor MJ; Gray J; Cortes J; Baselga J; Marangoni E; Welm AL; Aparicio S; Serra V; Garnett MJ; Caldas C
    Cell; 2016 Sep; 167(1):260-274.e22. PubMed ID: 27641504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology.
    Ji S; Feng L; Fu Z; Wu G; Wu Y; Lin Y; Lu D; Song Y; Cui P; Yang Z; Sang C; Song G; Cai S; Li Y; Lin H; Zhang S; Wang X; Qiu S; Zhang X; Hua G; Li J; Zhou J; Dai Z; Wang X; Ding L; Wang P; Gao D; Zhang B; Rodriguez H; Fan J; Clevers H; Zhou H; Sun Y; Gao Q
    Sci Transl Med; 2023 Jul; 15(706):eadg3358. PubMed ID: 37494474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity.
    Bruun J; Kryeziu K; Eide PW; Moosavi SH; Eilertsen IA; Langerud J; Røsok B; Totland MZ; Brunsell TH; Pellinen T; Saarela J; Bergsland CH; Palmer HG; Brudvik KW; Guren T; Dienstmann R; Guren MG; Nesbakken A; Bjørnbeth BA; Sveen A; Lothe RA
    Clin Cancer Res; 2020 Aug; 26(15):4107-4119. PubMed ID: 32299813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity, inherent and acquired drug resistance in patient-derived organoid models of primary liver cancer.
    Xian L; Zhao P; Chen X; Wei Z; Ji H; Zhao J; Liu W; Li Z; Liu D; Han X; Qian Y; Dong H; Zhou X; Fan J; Zhu X; Yin J; Tan X; Jiang D; Yu H; Cao G
    Cell Oncol (Dordr); 2022 Oct; 45(5):1019-1036. PubMed ID: 36036881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening.
    Broutier L; Mastrogiovanni G; Verstegen MM; Francies HE; Gavarró LM; Bradshaw CR; Allen GE; Arnes-Benito R; Sidorova O; Gaspersz MP; Georgakopoulos N; Koo BK; Dietmann S; Davies SE; Praseedom RK; Lieshout R; IJzermans JNM; Wigmore SJ; Saeb-Parsy K; Garnett MJ; van der Laan LJ; Huch M
    Nat Med; 2017 Dec; 23(12):1424-1435. PubMed ID: 29131160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.
    Myojin Y; Kodama T; Maesaka K; Motooka D; Sato Y; Tanaka S; Abe Y; Ohkawa K; Mita E; Hayashi Y; Hikita H; Sakamori R; Tatsumi T; Taguchi A; Eguchi H; Takehara T
    Clin Cancer Res; 2021 Feb; 27(4):1150-1161. PubMed ID: 33288659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomic profiling of intra-tumor heterogeneity using a large organoid biobank of liver cancer.
    Yang H; Cheng J; Zhuang H; Xu H; Wang Y; Zhang T; Yang Y; Qian H; Lu Y; Han F; Cao L; Yang N; Liu R; Yang X; Zhang J; Wu J; Zhang N
    Cancer Cell; 2024 Apr; 42(4):535-551.e8. PubMed ID: 38593780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver organoids: a promising three-dimensional model for insights and innovations in tumor progression and precision medicine of liver cancer.
    Chen Y; Liu Y; Chen S; Zhang L; Rao J; Lu X; Ma Y
    Front Immunol; 2023; 14():1180184. PubMed ID: 37334366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Organoids as research models for hepatocellular carcinoma.
    Yu JH; Ma S
    Exp Cell Res; 2022 Feb; 411(1):112987. PubMed ID: 34942189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Establishment of a living biobank : Improved guidance of precision cancer care with in vitro and in vivo cancer models].
    Pauli C; Moch H; Rubin MA
    Pathologe; 2017 Nov; 38(Suppl 2):160-168. PubMed ID: 28956107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance of Lenvatinib in Hepatocellular Carcinoma.
    Guo J; Zhao J; Xu Q; Huang D
    Curr Cancer Drug Targets; 2022; 22(11):865-878. PubMed ID: 36267045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The action and resistance mechanisms of Lenvatinib in liver cancer.
    Buttell A; Qiu W
    Mol Carcinog; 2023 Dec; 62(12):1918-1934. PubMed ID: 37671815
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.